What is the main purpose of this 8-K filing?

The primary purpose of this 8-K filing is to officially announce Bristol Myers Squibb's financial results for the fourth quarter and the full year of 2022, and to provide investors with access to the relevant detailed information through accompanying exhibits.

Where can I find the detailed financial results and operational information?

Detailed financial results, supplemental information including non-GAAP reconciliations, and a presentation on financial and operating initiatives can be found in the exhibits of this 8-K filing (Exhibits 99.1, 99.2, and 99.3) and on the company's website (www.bms.com).

Does this filing contain specific financial figures, or does it just point to other documents?

This 8-K filing itself does not contain the detailed financial figures. Instead, it formally incorporates by reference the press release (Exhibit 99.1) and supplemental information (Exhibit 99.2) which contain the company's financial results and related data.

What is the significance of the Regulation FD disclosure mentioned?

The Regulation FD disclosure indicates that while the information is being made public to ensure fair disclosure, it is being furnished and not formally 'filed' with the SEC. This means it is not subject to the liabilities of Section 18 of the Securities Exchange Act of 1934, though it remains crucial for investors to understand the company's performance.

BMY 8-K: Earnings & Results & Regulation FD

Summary

Bristol Myers Squibb (BMY) has filed an 8-K report on February 2, 2023, to announce its financial results for the fourth quarter and full year of 2022. The report primarily directs investors to accompanying press releases, supplemental information, and presentations available on the company's website for detailed financial and operational insights. This filing serves as a formal notification of the release of these results, allowing investors to access comprehensive data regarding the company's performance. Investors are encouraged to review the furnished exhibits, including the Earnings Press Release (Exhibit 99.1) and Supplemental Information (Exhibit 99.2), which contain the core financial figures and reconciliations for non-GAAP measures. Additionally, the Bristol Myers Presentation (Exhibit 99.3) offers further context on financial and operating initiatives. It's important to note that the information furnished under Regulation FD is not considered 'filed' for legal liability purposes under Section 18 of the Exchange Act, but it provides crucial data for investment decision-making.

Key Highlights

1BMY filed an 8-K on February 2, 2023, announcing Q4 and Full Year 2022 financial results.
2The filing incorporates by reference a press release (Exhibit 99.1) detailing the financial results.
3Supplemental financial information and non-GAAP reconciliations are provided as Exhibit 99.2.
4A presentation on financial and operating initiatives (Exhibit 99.3) was also made available.
5Investors can access these detailed financial results and presentations on the BMY website.
6The report includes information on both GAAP and non-GAAP financial measures.
7The furnished information is not deemed 'filed' for legal purposes under Section 18 of the Exchange Act.

BRISTOL MYERS SQUIBB CO 8-K Report, Financial Results (Feb 2, 2023)

Summary

Key Highlights

Frequently Asked Questions